Meet FDA Investigator Conner Mann: Insights from 22 Completed Inspections

Every FDA inspection tells a story, and so does every investigator. If you’re in QA or regulatory compliance, you know that no two inspectors operate the same way. Some zero in on data integrity failures, others scrutinize your CAPA program line by line, and a few will track batch records across multiple systems just to catch a discrepancy. The bottom line is this: knowing your inspector’s patterns, priorities, and pressure points can make or break your next audit outcome.

Let’s talk about Conner Mann, an FDA investigator with 13 completed inspections. Their record offers a window into what life sciences facilities can expect and how you can use these insights to get inspection-ready.

Who is Conner Mann?

Conner Mann is an FDA field investigator who has conducted 22 documented inspections of pharmaceutical manufacturing, biologics, and medical device facilities across the United States.

Their work has been concentrated in the Northeast and Midwest regions, reflecting FDA priorities in those manufacturing hubs. Mann has handled both routine surveillance inspections, aimed at ensuring ongoing compliance, and for-cause inspections, where prior concerns or complaints prompted a deeper look.

Those who have experienced a Conner Mann FDA inspection describe the approach as thorough yet constructive. Mann isn’t looking to penalize companies for minor infractions but does expect clear, consistent documentation and credible evidence that quality systems are truly effective. When weaknesses are identified, Mann is known for providing actionable feedback on how to improve, making the process demanding but ultimately fair.

The Numbers: Conner Mann by the Data

A deeper look at Mann’s record reveals some meaningful patterns that QA teams can learn from.

• Total inspections: 13
• Form 483s issued: 10
• Warning Letters issued: 1
• Inspection duration

• Longest: 30 days
• Shortest: 1 day
• Average: 7.8 days
• Most Common Observation Categories:
  • CAPA deficiencies
  • Environmental monitoring lapses
  • Data integrity failures (electronic records and audit trails)
  • Inadequate training documentation

The data paints a clear picture: Mann expects not just compliance on paper, but evidence that systems are actually delivering the intended level of control, reliability, and quality.

Patterns Emerging from Mann’s Inspections

Every inspector has tendencies. Here are some patterns that emerge from Mann’s record:

1. Focus on Documentation Practices

In nearly every Form 483 Mann has issued, at least one observation pointed to incomplete, inconsistent, or outdated documentation, whether in batch records, deviation reports, or SOPs. For Mann, documentation isn’t just a requirement; it’s a proxy for the effectiveness of your overall system.

2. Scrutiny of Sterility Assurance

Facilities engaged in biologics or aseptic processing operations are likely to face extra scrutiny from Mann on environmental controls, cleanroom maintenance, and contamination prevention measures. Weak or poorly trended monitoring data has often drawn citations in these settings.

3. Attention to CAPA Systems

Mann doesn’t just check whether a CAPA log exists. They routinely assess how CAPAs are initiated, whether root causes were meaningfully identified, how timelines were managed, and whether effectiveness checks were conducted. Superficial fixes tend to get flagged.

These patterns tell you exactly where to focus if you know Mann, or someone like them, is coming to your site.

Why This Data is Valuable for QA and Compliance Teams

Understanding an investigator’s tendencies isn’t just trivia — it helps you prioritize your preparation. Your team’s time is limited, and you can’t fix everything at once.

If you know Mann frequently cites gaps in training records, you can run an internal audit on that area and fix the gaps now. If you know they zero in on environmental monitoring trends, you can make sure your trending reports are current and well-documented.

Being aware of their higher-than-average 483 issuance rate can also help you set expectations internally, prepare your staff to remain calm, and be ready to present evidence quickly when asked.

It’s not about gaming the system. It’s about aligning your preparation with the reality of how FDA inspections actually unfold, which builds confidence for both you and your team.

How Atlas Compliance Helps You Prepare Smarter

Here’s where the right tools make all the difference. Atlas Compliance gives you instant access to investigator profiles, inspection histories, and trend data across the FDA. You can:

• Look up any investigator’s most-cited issues.
• Benchmark your facility against others in your industry.
• Get alerts when inspection trends shift or new areas of focus emerge.
• Generate a pre-inspection checklist tailored to your site and assigned investigator.

QA managers using Atlas have reported faster prep times, fewer surprises, and better inspection outcomes.

Pro Tips for Preparing if Conner Mann (or Someone Like Them) is Assigned

If you find out Mann has been assigned to your upcoming inspection, don’t wait to react. Here are five concrete steps to get ahead:

1. Audit Your Documentation Thoroughly: Review batch records, deviation reports, and SOPs for completeness, clarity, and consistency. Watch out for outdated or conflicting procedures.
2. Trend Your Environmental Monitoring Data: Prepare at least 12 months of cleanroom and equipment monitoring trends. Make sure out-of-limit events have documented investigations and follow-up actions.
3. Scrutinize Your CAPA Log: Verify closure timelines, documented root causes, and evidence of effectiveness checks for recent CAPAs.
4. Run a Mock Inspection: Focus on sterility assurance, data integrity, and CAPA systems. Identify weak spots and address them before the real thing.
5. Brief and Drill Your Team: Train staff at all levels to answer questions clearly and confidently. Remind them to speak only of what they know, and to refer to documentation when needed.

These steps not only prepare you for a visit from Mann but strengthen your compliance posture overall.

Final Takeaway

You can’t predict every twist and turn of an FDA inspection. But you can anticipate much more than you think, if you know who you’re dealing with.

Conner Mann’s record shows a thoughtful but exacting approach, with particular attention to CAPAs, data integrity, environmental controls, and documented trends. The good news? These are all areas your team can strengthen in advance.

By aligning your preparation with the realities of FDA inspections and leveraging tools like Atlas to work smarter, you can turn inspection day from a source of stress into an opportunity to showcase the strength of your systems.